Novo Nordisk Reports H1 2023 Revenue of $15.86 Billion, Driven by Semaglutide's $9 Billion Surge

Today (August 10), Novo Nordisk released its financial report for the first half of 2023 (January 1, 2023 to June 30, 2023): Net sales were107.667 billion Danish kroner(Approximately 15.885 billion USD), compared to 83.296 billion Danish kroner (12.289 billion US dollars) in the same period last year,An increase of 29% year-on-year, with a net profit of 39.242 billion Danish kroner (5.790 billion US dollars),Last year's same period was 27.528 billion Danish kroner (4.061 billion US dollars),Increased by 43% year-on-year。

Image Source: Novo Nordisk Official Website

Diabetes and Obesity BusinessRevenue reached99 billion Danish kroner (14.607 billion US dollars)，Increased by 36% year-on-year.Mainly due to a 49% year-on-year increase in GLP-1 business sales and a 158% year-on-year increase in obesity care business sales, reaching DKK 18.1 billion (USD 2.67 billion).

Image Source: Novo Nordisk Official Website

Among them, subcutaneous injection formulationsOzempicSales amounted to 41.741 billion Danish kroner (6.169 billion US dollars), oral formulationsRybelsusSales amounted to DKK 8.344 billion (USD 1.233 billion), with the combined contribution reaching DKK 50.085 billion (USD 7.402 billion).Wegovy and SaxendaSales were DKK 12.081 billion (USD 1.782 billion) and DKK 6.067 billion (USD 895 million), respectively.

Yesterday (August 9), Novo Nordisk announced that treatment with a 2.4mg dose of semaglutide can reduce the risk of cardiovascular events, a side effect in overweight/obese patients, by 20%.

The following is the financial situation listed by Novo Nordisk:

Image Source: Novo Nordisk Official Website

Looking ahead to 2023, Novo Nordisk expects full-year sales to grow by 27%-33%, with operating profit increasing by 31%-37%.

Image Source: Novo Nordisk Official Website

Editor: Mu Mian

Disclaimer: This article is a reprint from PharmNet. All images and text are owned by the original author. The purpose of the reprint is to convey more information and does not represent the views of this platform. If there are any issues regarding content, copyright, or other matters, please leave a message on this platform, and we will address it promptly.